Submit site search
  • Risk Factor for Parkinson’s Discovered in Genes From People of African Descent

    Read NPR's coverage of GP2's historic GBA1 finding. This article by Jon Hamilton includes interviews with ASAP's Managing Director, Dr. Ekemini A. U. Riley, and lead GP2 study researchers, Andy Singleton and Sara Bandres-Ciga.

  • Gene Variant Found Linking People of African Descent to Higher Parkinson’s Risk

    Dr. Ekemini A. U. Riley, managing director of ASAP, joins PBS NewsHour to discuss findings from the GBA1 discovery and the power of collaborative, open science to unlock discoveries for populations traditionally underrepresented in research.

  • UNILAG Researchers Unravel Novel Parkinson’s Genetic Risk Factor in Africans

    The Guardian Nigeria reports on GP2 and its collaboration with the University of Lagos (UNILAG) to uncover a genetic variant that increases the risk of PD in Africans and African admixed populations.

  • The Components of GP2’s Fifth Data Release

    In May 2023, GP2 announced the fifth data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 7,462 additional new complex disease participants and 487 new monogenic disease participants, adding to the previous releases from the Complex and Monogenic Networks.

  • The Components of GP2’s Fourth Data Release

    In February 2023, GP2 announced the fourth data release on the Terra platform in collaboration with AMP® PD. This release includes 2,583 additional new complex disease participants, adding to the previous releases from the Complex and Monogenic Networks.

  • GP2 Cohort Dashboard Now Includes New Ancestry Categories

    The updated GP2 Cohort dashboard now includes additional ancestry information across cohort samples that have already been processed and shared with the AMP® PD platform.

  • 2022: A Year in Review

    ASAP reflects on the progress made in 2022 toward our vision of advancing collaborative, transparent research processes and environments that deliver faster and better outcomes in Parkinson’s disease research.

  • The Components of GP2’s Third Data Release

    In October 2022, GP2 announced the third data release on the Terra platform in collaboration with AMP® PD. This release includes 6,330 additional new complex disease participants, adding to the previous releases from the Complex and Monogenic Networks.

  • GP2 Trainees Offer Perspective on Annual Investigators Meeting

    GP2's trainee network consists of nearly 150 members worldwide. Some of these trainees recently attended the inaugural Annual Investigators Meeting in Madrid, Spain. Take a look at their impressions of the meeting and GP2's ambitious work.

  • The Components of GP2’s Second Data Release

    In April 2022, GP2 announced the second data release on the Terra platform in collaboration with AMP® PD. This release contains data from both complex and monogenic GP2 networks. The complex disease data now consists of a total of 8,644 genotyped participants (5,249 PD, 3,395 non-PD).

  • GP2 Celebrates the International Day of Women and Girls in Science

    Women scientists have historically gone unrecognized for their fundamental contributions. Today and every day, GP2 recognizes and works to empower women to lead, create, and innovate in the field of PD genetics around the world.

  • The Components of GP2’s First Data Release

    In December 2021, GP2 announced its first GP2 data release on the AMP® PD platform. The data available consists of 4,908 participants (3,434 PD, 1,474 non-PD) from the CORIELL, Baylor College of Medicine (BCM), and BCM-University of Maryland (UMD) cohorts.

  • GP2 Awards New Trainees

    As the demand for Parkinson's disease genetics specialists continues to grow, GP2 is committed to providing opportunities and training to researchers around the world. With GP2's support, the work and discoveries of our next generation of researchers will accelerate the path to a cure for PD.

  • Promoting Diversity, Equity and Inclusion in Parkinson’s Research and Care

    Medical Xpress reports on The Michael J. Fox Foundation for Parkinson's Research’s work to diversify PD research.

  • GP2-Funded Training Opportunity: Online Courses by FAES at the NIH

    Researchers looking to level up their bioinformatics and data science skills are invited to apply for GP2 funding to attend online courses delivered by the Foundation for Advanced Education in the Sciences (FAES) at the National Institutes of Health (NIH). Click below to find out more and access the application.

  • The Genetic Architecture of Parkinson’s Disease in Latino Populations

    An international research team led by the Cleveland Clinic has presented the most comprehensive characterization of the underlying genetic basis for Parkinson’s disease (PD) in Latinos to date, marking an important step towards more inclusive PD genetic research.

  • First-of-its-Kind DNA Biobank Opens in Peru

    ASAP, through GP2 and in partnership with LARGE-PD and the MJFF, celebrated a shared milestone with the inauguration of the DNA Biobank at the Instituto Nacional de Ciencias Neurológicas. The Biobank will help accelerate collaboration and greater genetic representation of Latin American participants in research.

  • Point of View: Open Science Takes On Parkinson’s Disease

    This article, authored by Drs. Ekemini A. U. Riley and Randy Schekman, delves into the ASAP initiative, highlighting its emphasis on open science and collaboration to improve understanding of the biology underlying the onset and progression of Parkinson’s disease.

Load More